---
title: Boston Scientific (BSX) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/bsx
ticker: BSX
as_of: 2026-10-17
sector: Healthcare
industry: Medical - Devices
---
# Boston Scientific (BSX)

Boston Scientific (BSX) closed at $44.39 on Oct 16, 2026, undervalued by 20% vs its model value of $55.69 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $44.39 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $55.69 |
| Price vs model | undervalued by 20% vs model |
| Range of that model | $32.28 – $130.87 |
| Market value | $64.3B |
| P/E (fiscal 2025) | 22.9 |
| Net margin (fiscal 2025) | 14.4% |
| Free cash flow (fiscal 2025) | $3.7B |
| Dividend yield (trailing twelve months) | 0.00% |
| Beta | 0.57 |
| Cost of capital (WACC) | 7.49% |
| Business classification | Mature & Stable (Moderate growth (~19% recent), Moderate margins (14% net margin), Highly cyclical earnings, Strong FCF yield (5.7%)) |

## On the stock lists

| List | Place | Figure | Page |
| --- | ---: | ---: | --- |
| Worst performing this year | #5 | −53.4% | https://sweetvaluelab.com/lists/worst-performing-this-year |
| Insider buying | #6 | $9.5M | https://sweetvaluelab.com/lists/insider-buying |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $55.69 | $32.28 | $130.87 |
| DCF · Perpetuity growth · 10y | cross check | $63.46 | $37.86 | $146.92 |
| DCF · EBITDA exit · 5y | cross check | $85.80 | $65.49 | $109.60 |
| DCF · EBITDA exit · 10y | cross check | $91.15 | $65.85 | $124.46 |
| P/E · peers | cross check | $83.86 | $73.52 | $94.19 |
| P/E · own history | cross check | $188.06 | $153.77 | $218.65 |
| PEG | sanity check | $59.81 | $59.81 | $59.81 |
| EV/EBITDA · peers | cross check | $86.93 | $67.73 | $106.12 |
| EV/Revenue · peers | cross check | $64.35 | $54.76 | $68.99 |
| Earnings power value | cross check | $5.27 | $3.33 | $8.18 |
| Dividend discount | cross check | $0.00 | $0.00 | $0.00 |

## Insider activity (SEC Form 4)

Past 90 days: 6 open-market buys ($9.5M) and 0 open-market sales ($0); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Sep 2, 2026 | O'Connor Padraig Andrew | EVP, Global Operations | Option/RSU exercise | 1,171 | $0 |
| Sep 2, 2026 | O'Connor Padraig Andrew | EVP, Global Operations | Tax withholding | 567 | $27,425.8 |
| Sep 2, 2026 | O'Connor Padraig Andrew | EVP, Global Operations | Option/RSU exercise | 1,171 | $0 |
| Aug 25, 2026 | Morano Susan E | Director | Open-market buy | 2,040 | $100,407.8 |
| Aug 11, 2026 | Woodworth Emily | SVP, Global Controller and CAO | Discretionary transaction | 2,930 | $149,986.7 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Oct 7, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 8.01 Other Events; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/885725/000088572526000064/bsx-20261001.htm |
| Sep 23, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers | https://www.sec.gov/Archives/edgar/data/885725/000088572526000061/bsx-20260921.htm |
| Sep 8, 2026 | 8-K | 1.05 Material Cybersecurity Incident | https://www.sec.gov/Archives/edgar/data/885725/000088572526000059/bsx-20260907.htm |
| Aug 26, 2026 | 8-K | 8.01 Other Events | https://www.sec.gov/Archives/edgar/data/885725/000088572526000056/bsx-20260826.htm |
| Aug 3, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Lee Ainslie | 2026-06-30 | 5,937,553 | $253.4M |
| Sarah Ketterer | 2026-06-30 | 720,339 | $30.7M |
| Bridgewater | 2026-06-30 | 442,036 | $18.9M |
| Dodge & Cox | 2026-06-30 | 87,485 | $3.7M |

6 tracked managers in all.

## About

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treati…

---

Source: https://sweetvaluelab.com/stocks/bsx (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.